A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Intravenous Dose Study to Examine the Safety, Tolerability, and Pharmacokinetics of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects
Sponsor: Theravance Biopharma
Terminated
For business reasons
Other terminated trials from Theravance Biopharma
This PHASE1 trial investigates Gastrointestinal Motility Disorder and is currently terminated or withdrawn. Theravance Biopharma leads this study, which shows 11 recorded versions since 2012 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE1
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE1
▶ Show 6 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE1
-
Oct 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Jun 2018 — Oct 2018 [monthly]
Terminated PHASE1
-
Sep 2017 — Jun 2018 [monthly]
Terminated PHASE1
Status: Completed → Terminated
-
Feb 2017 — Sep 2017 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Sep 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Theravance Biopharma
For direct contact, visit the study record on ClinicalTrials.gov .